## Key figures - as of October 5th

<table>
<thead>
<tr>
<th>Age range</th>
<th>% of Population</th>
<th>CT Population</th>
<th>Number</th>
<th>%</th>
<th>Fully vaccinated</th>
<th>Number</th>
<th>%</th>
<th>Third doses</th>
<th>Number</th>
<th>%</th>
<th>Total Doses Administered</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Ages</td>
<td>100%</td>
<td>3,565,287</td>
<td>2,551,809</td>
<td>71.6%</td>
<td>2,359,658</td>
<td>66.2%</td>
<td>71,096</td>
<td>2.0%</td>
<td>4,807,912</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5+</td>
<td>95%</td>
<td>3,383,577</td>
<td>2,551,692</td>
<td>75.4%</td>
<td>2,359,586</td>
<td>69.7%</td>
<td>71,096</td>
<td>2.1%</td>
<td>4,807,735</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12+</td>
<td>87%</td>
<td>3,105,947</td>
<td>2,551,637</td>
<td>82.2%</td>
<td>2,359,567</td>
<td>76.0%</td>
<td>71,096</td>
<td>2.3%</td>
<td>4,807,661</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16+</td>
<td>82%</td>
<td>2,929,347</td>
<td>2,430,126</td>
<td>83.0%</td>
<td>2,253,931</td>
<td>76.9%</td>
<td>71,040</td>
<td>2.4%</td>
<td>4,580,468</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18+</td>
<td>80%</td>
<td>2,837,847</td>
<td>2,358,016</td>
<td>83.1%</td>
<td>2,188,364</td>
<td>77.1%</td>
<td>70,983</td>
<td>2.5%</td>
<td>4,442,783</td>
<td></td>
<td></td>
</tr>
<tr>
<td>35+</td>
<td>57%</td>
<td>2,047,745</td>
<td>1,790,056</td>
<td>87.4%</td>
<td>1,682,945</td>
<td>82.2%</td>
<td>68,811</td>
<td>3.4%</td>
<td>3,419,545</td>
<td></td>
<td></td>
</tr>
<tr>
<td>45+</td>
<td>45%</td>
<td>1,620,604</td>
<td>1,442,258</td>
<td>89.0%</td>
<td>1,364,887</td>
<td>84.2%</td>
<td>65,981</td>
<td>4.1%</td>
<td>2,785,341</td>
<td></td>
<td></td>
</tr>
<tr>
<td>55+</td>
<td>32%</td>
<td>1,143,699</td>
<td>1,052,752</td>
<td>92.0%</td>
<td>999,850</td>
<td>87.4%</td>
<td>61,936</td>
<td>5.4%</td>
<td>2,056,477</td>
<td></td>
<td></td>
</tr>
<tr>
<td>65+</td>
<td>18%</td>
<td>630,244</td>
<td>590,463</td>
<td>93.7%</td>
<td>560,004</td>
<td>88.9%</td>
<td>53,599</td>
<td>8.5%</td>
<td>1,186,315</td>
<td></td>
<td></td>
</tr>
<tr>
<td>75+</td>
<td>8%</td>
<td>277,425</td>
<td>252,594</td>
<td>91.0%</td>
<td>238,847</td>
<td>86.1%</td>
<td>26,364</td>
<td>9.5%</td>
<td>511,752</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data as reported to CT DPH Immunization Information System (IIS) CT WiZ.
All ages estimate includes 172 people with unknown age.
Age coverage: Specific age groups

Doses Reported by 10/04/2021

<table>
<thead>
<tr>
<th>Age Range</th>
<th>% of Population</th>
<th>CT Population</th>
<th>At least one dose*</th>
<th>% Coverage with a Least One Dose*</th>
<th>Fully Vaccinated**</th>
<th>% Fully Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;12</td>
<td>13%</td>
<td>459,340</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>12-15</td>
<td>5%</td>
<td>176,600</td>
<td>121,511</td>
<td>68.8%</td>
<td>105,636</td>
<td>59.8%</td>
</tr>
<tr>
<td>16-17</td>
<td>3%</td>
<td>91,500</td>
<td>72,110</td>
<td>78.8%</td>
<td>65,567</td>
<td>71.7%</td>
</tr>
<tr>
<td>18-24</td>
<td>10%</td>
<td>342,073</td>
<td>236,567</td>
<td>69.2%</td>
<td>208,739</td>
<td>61.0%</td>
</tr>
<tr>
<td>25-34</td>
<td>13%</td>
<td>448,029</td>
<td>331,393</td>
<td>74.0%</td>
<td>296,680</td>
<td>66.2%</td>
</tr>
<tr>
<td>35-44</td>
<td>12%</td>
<td>427,141</td>
<td>347,798</td>
<td>81.4%</td>
<td>318,058</td>
<td>74.5%</td>
</tr>
<tr>
<td>45-54</td>
<td>13%</td>
<td>476,905</td>
<td>389,506</td>
<td>81.7%</td>
<td>365,037</td>
<td>76.5%</td>
</tr>
<tr>
<td>55-64</td>
<td>14%</td>
<td>513,455</td>
<td>462,289</td>
<td>90.0%</td>
<td>439,846</td>
<td>85.7%</td>
</tr>
<tr>
<td>65-74</td>
<td>10%</td>
<td>352,819</td>
<td>337,869</td>
<td>95.8%</td>
<td>321,157</td>
<td>91.0%</td>
</tr>
<tr>
<td>75-84</td>
<td>5%</td>
<td>186,095</td>
<td>178,285</td>
<td>95.8%</td>
<td>168,663</td>
<td>90.6%</td>
</tr>
<tr>
<td>85+</td>
<td>3%</td>
<td>91,330</td>
<td>74,309</td>
<td>81.4%</td>
<td>70,184</td>
<td>76.8%</td>
</tr>
<tr>
<td>Grand Total</td>
<td></td>
<td>3,565,287</td>
<td>2,551,637</td>
<td>71.6%</td>
<td>2,359,567</td>
<td>66.2%</td>
</tr>
</tbody>
</table>

*At least one dose includes individuals who have received one dose of Pfizer, Moderna, or J&J
**Fully vaccinated includes individuals who received one dose of J&J, two doses of Moderna, or two doses of Pfizer.
Total excludes 172 people with unknown age
Information from the weekly state profile published by the CDC. Archived reports can be found here.
Booster Update

CDC recommendations:
- People 65 years and older and residents in long-term care settings should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
- People aged 50–64 years with underlying medical conditions should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
- People aged 18–49 years with underlying medical conditions may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks, and
- People aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks.

Ensuring patients receive a COVID vaccine at the appropriate interval:
- Verify the vaccine information, including the brand and date(s) a patient received their previous COVID-19 vaccine doses using CT WiZ; or
- Review the Centers for Disease Control and Prevention (CDC) Vaccination Card, VAMS Certificate, CT WiZ Certificate, or other documentation of the recipient’s vaccination record; or
- If neither of the above are possible, ask the patient for the vaccine brand(s) and dates of previous COVID-19 doses received during the scheduling process (and including logic in scheduling systems to ensure appropriate interval).
Upcoming milestones

Moderna & J&J boosters
October 14-15: VRBPAC will meet to discuss the Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine for the administration of a booster dose, following completion of the primary series, to individuals 18 years of age and older. On October 15, 2021, the committee will meet to discuss the Janssen J&J COVID-19 vaccine for the administration of a booster dose, to individuals 18 years of age and older. Meeting information and the link to the live streamed meeting is available here.

Pfizer 5-11 age expansion
October 26: The FDA anticipates receiving a request from Pfizer to amend its emergency use authorization to allow the use of its COVID-19 vaccine in children 5 through 11 years of age. In anticipation of the request, the FDA is moving forward with scheduling a meeting on Oct. 26 to inform the agency’s decision-making. Meeting information is not yet posted, but the press release is available here.

Do not stock up on supply in anticipation of upcoming approvals

Product formats, dosing, and kit contents may be modified based on approved regimens!
Action Required: Take the 5-11 Survey!

Childhood Vaccination Survey
In anticipation of approval of vaccine for 5–11-year-olds we are collecting data from our providers. Please make sure that someone in your organization completes this survey by Friday, October 8, 2021: https://www.surveymonkey.com/r/ChildrenVaxPlanning

All providers should complete this survey so we have a current, accurate listing of providers that will be offering vaccines to children at the time of authorization!
Bulletin Updates

Standing Orders
The Pfizer standing order was updated on 9/28 to reflect the recommendations for booster doses. It can be found here.

CDC Health Advisory
CDC HAN 453: COVID-19 Vaccination for Pregnant People to Prevent Serious Illness, Deaths, and Adverse Pregnancy Outcomes from COVID-19 was shared with CoVP providers on 9/30 and is available here. Please read this important communication from the CDC and encourage COVID-19 vaccination for your pregnant patients.

The increased circulation of the highly contagious Delta variant, the low vaccine uptake among pregnant people, and the increased risk of severe illness and pregnancy complications related to COVID-19 infection among pregnant people make vaccination for this population more urgent than ever.

The CDC webpage COVID-19 Vaccines While Pregnant or Breastfeeding contains some key messages for you to share with your patients.

Vaccine Expiration
Providers who have Moderna vaccine expiring in the near future should continue to store in appropriate temperatures. CDC has announced they expect an extension of the expiration based on additional stability data from the manufacturers.
Multicomponent Strategies to Prevent SARS-CoV-2 Transmission — Nine Overnight Youth Summer Camps, United States, June–August 2021

Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021

CT WiZ/VAMS Update
VAMS Assistance, Updating Demographics in CT WiZ and DPH Social Media Subscription

Version 0.1
10/6/2021
VAMS Assistance

Tier 2 Support

Selecting Help from VAMS

Tier 1 Support

Phone

Email
Updating Demographics in CT WiZ

Click:
- Click the blue Update link on the Immunizations page

Complete:
- Complete the Patient Eligibility field

Click:
- Click Update on the Patient Demographics page

Return:
- Return to the Immunizations page to log vaccination
To ask a question, please raise your hand using the hand icon on your screen, type your question in the chat box or if you are on the phone press *6 to unmute yourself.

If you have additional questions after the meeting, please feel free to email them to DPH.Immunizations@ct.gov

You can fill out a help desk ticket by visiting https://dph-cthelpdesk.ct.gov/Ticket